ClinicalTrials.gg
RecruitingNCT03807128MYRACLEUpdated Jul 14, 2025

MYeloma Resistance And Clonal Evolution

An observational study in Multiple Myeloma, sponsored by Nantes University Hospital. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Nantes University Hospital · Observational

How we know

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Multiple Myeloma by Nantes University Hospital — 1 open to participants now, 6 under way, none of them phase 3. Multiple Myeloma · Nantes University Hospital.

Started
2019
with 1 other
Observational
2 of 17
1 open now
Registered
11th of 17
by date

Among the 17 studies in Multiple Myeloma by Nantes University Hospital, this one is one of 2 that started in 2019, is one of 2 observational ones, and was the 11th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 17 studies in Multiple Myeloma by Nantes University Hospital is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Multiple Myeloma by Nantes University Hospital, or all of them as a file.
02

Study summary

Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.

Read the detailed description

The MYRACLE cohort study aims at including all patients (>18 years old) who are diagnosed with MM in any stage of the disease and treated in specialized oncology centers in 2 public hospitals in Northwestern France. Any such patient providing a signed informed consent is included. All subjects are followed up until refusal to participate in the study, emigration or death. The MYRACLE follow-up is continuous and collects data on socio-economic status, medical status, MM therapies and associated events (resistance, side effects). Participants also complete standardized quality of life (QOL) questionnaires. In addition, participants are asked to donate blood samples that will support ex vivo analysis of expression and functional assays required to uncover predictive biomarkers and companion diagnostics. If diagnostic biopsies are performed during the course of the disease, extracted biological samples are kept in a dedicated biobank.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Myeloma
  • Cohort
  • Resistance
  • Quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population corresponds to multiple myeloma patients managed in the hematology departments of the University Hospital of Nantes and the CHD of La Roche sur Yon.

Recruitment of the hematology departments of the University Hospital of Nantes and CHD of La Roche sur Yon makes it possible to envisage an annual recruitment of 60 new myeloma diagnoses, and an annual number of 80 relapses. These data are estimated from the number of files submitted to the Multidisciplinary Collaborative Meeting (RPN) and the annual inclusion number in clinical trials. This number represents a cohort of about 140 inclusions per year. The average number of visits can be estimated at 1.5 / year per patient.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014)
  • Patient having consented to participate in the study and his/her biocollection
  • Patient affiliated to or benefiting from a social security scheme or similar

Exclusion criteria

Exclusion Criteria:

  • Minors
  • Major under guardianship or curatorship
  • Protected persons.
  • Pregnant or breast-feeding women
  • Persons benefiting from the AME
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,400 participants (estimated)
Patient registry
No

Groups and cohorts

  • MYRACLE patients

    Other: Prélèvement sanguin (2*4mL) ou médullaire (2mL) · Other: Data collection through questionnaires

Interventions

  • OtherPrélèvement sanguin (2*4mL) ou médullaire (2mL)

    Additional blood (2\*4mL) or bone marrow (2mL) sample depending on clinical presentation of disease

  • OtherData collection through questionnaires

    Collection of quality of life and occupational exposure data via questionnaires

06

What researchers measure

Primary outcomes

  1. Describe the mechanisms of resistance of myeloma cells.

    Number of resistance.

    Time frame: 15 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Derrien J, Gastineau S, Frigout A, Giordano N, Cherkaoui M, Gaborit V, Boinon R, Douillard E, Devic M, Magrangeas F, Moreau P, Minvielle S, Touzeau C, Letouze E. Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation. Nat Cancer. 2023 Nov;4(11):1536-1543. doi: 10.1038/s43018-023-00625-9. Epub 2023 Aug 31. PubMed 37653140 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Feb 2034, 180 months after the start.

Of 173 non-industry observational studies under Multiple Myeloma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 31. This study's planned 180 months is above that.

Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2018
First posted
Jan 16, 2019
StartActual
Feb 11, 2019
Primary completionEst.
Feb 11, 2034
CompletionEst.
Feb 11, 2049
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03807128
Responsible party
Sponsor
First posted
Jan 16, 2019
Start date
Feb 11, 2019
Primary completion
Feb 11, 2034 (estimated)
Completion
Feb 11, 2049 (estimated)
Last update
Jul 14, 2025

Study contacts

Cyrille TOUZEAU, PU
Contact
cyrille.touzeau@chu-nantes.fr
02 40 08 32 71
Cyrille TOUZEAU, PU
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion